Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

They provided evidence to guide treatment decisions for COPD patients. Study: Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease ...

a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice. Design New user cohort study. Setting Longitudinal commercial US ...

Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms. Israel-based Teva said the ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

End-stage COPD is the most severe stage of chronic obstructive ... Long-acting bronchodilators can be used every day to help control symptoms. An inhaler is a pocket-sized portable device, while ...